Ratings Amway (Malaysia) Holdings

Equities

End-of-day quote BURSA MALAYSIA Other stock markets 03:30:00 03/05/2024 am IST			5-day change	1st Jan Change
7.3 ^MYR	+0.55%		+0.55%	+24.15%

23/04	Amway Holdings Berhad Announces Retirement of Dato' Abdullah Thalith Bin Md Thani as Independent and Non Executive Member of Audit Committee, Effective 23 May 2024	CI
23/04	Amway Holdings Berhad Announces Retirement of Dato' Abdullah Thalith Bin Md Thani as Independent and Non Executive Director, Effective 23 May 2024	CI

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

This company will be of major interest to investors in search of a high dividend stock.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.

	1st Jan change	Capi.	ESG Refinitiv
AMWAY (MALAYSIA) HOLDINGS	+24.15%	251M	-
ELI LILLY AND COMPANY	+26.08%	681B	C+
NOVO NORDISK A/S	+21.85%	556B	B
JOHNSON & JOHNSON	-4.77%	361B	C+
MERCK & CO., INC.	+16.97%	325B	B-
ABBVIE INC.	+5.69%	285B	C+
ASTRAZENECA PLC	+13.68%	235B	B+
NOVARTIS AG	+3.65%	199B	B-
ROCHE HOLDING AG	-11.12%	189B	A+
PFIZER, INC.	-3.40%	157B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality